Exelixis to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021Business Wire • 01/04/21
Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid CancerBusiness Wire • 12/21/20
Exelixis In-Licenses Aurigene's Novel CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Clinical Trial in Advanced Solid TumorsBusiness Wire • 12/07/20
Exelixis In-Licenses Iconic Therapeutics' Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug ApplicationBusiness Wire • 12/02/20
Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Evercore ISI 3rd Annual HealthCONx (Transcript)Seeking Alpha • 12/01/20
Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic TherapyBusiness Wire • 11/27/20
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in DecemberBusiness Wire • 11/23/20
Exelixis, Inc. (EXEL) CEO Michael Morrissey Presents at Stifel 2020 Virtual Healthcare Conference (Transcript)Seeking Alpha • 11/18/20
Exelixis, Inc. (EXEL) CEO Michael Morrissey Presents at Credit Suisse 29th Annual Virtual Healthcare Conference (Transcript)Seeking Alpha • 11/12/20
Exelixis' (EXEL) CEO Mike Morrissey on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/06/20
Exelixis Announces Third Quarter 2020 Financial Results and Provides Corporate UpdateBusiness Wire • 11/05/20
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in NovemberBusiness Wire • 11/02/20
Exelixis' (EXEL) Applications for Cabometyx-Opdivo Combo Accepted (Revised)Zacks Investment Research • 10/28/20